- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Greenwich LifeSciences verschiebt Vorlage des Jahresberichts | 1 | Investing.com Deutsch | ||
| Do | Greenwich LifeSciences delays annual report filing | 1 | Investing.com | ||
| Do | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Regarding Form 10-K Filing | 2 | GlobeNewswire (USA) | ||
| 23.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 22.04. | Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing | 1 | Seeking Alpha | ||
| 22.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing | 611 | GlobeNewswire (Europe) | STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 20.04. | Greenwich LifeSciences: Aktie steigt nach positiven Studiendaten zu Brustkrebsimpfstoff | 1 | Investing.com Deutsch | ||
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Greenwich LifeSciences reports Q1 cash balance of $10.5 million | 1 | Investing.com | ||
| 14.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Financing Strategy | 247 | GlobeNewswire (Europe) | STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 07.04. | Greenwich LifeSciences files patent claims for breast cancer therapy | 1 | Investing.com | ||
| 07.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential | 228 | GlobeNewswire (Europe) | STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 31.03. | Greenwich LifeSciences, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 19.03. | Greenwich LifeSciences: Phase-III-Studie wird auf City of Hope-Standorte ausgeweitet | 3 | Investing.com Deutsch | ||
| 19.03. | Greenwich LifeSciences expands Phase III trial to City of Hope sites | 1 | Investing.com | ||
| 19.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 | 3 | GlobeNewswire (USA) | ||
| 18.03. | Greenwich LifeSciences to present trial data at AACR meeting | 1 | Investing.com | ||
| 18.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Upcoming AACR Meeting | 1 | GlobeNewswire (USA) | ||
| 17.03. | Greenwich LifeSciences reports reduced cancer recurrence in trial | 14 | Investing.com | ||
| 17.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 | 215 | GlobeNewswire (Europe) | STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| KUROS BIOSCIENCES | 22,200 | +0,27 % | Was bei Kuros Biosciences gerade passiert: Das Warnsignal das die meisten Anleger jetzt übersehen - Was ich konkret unternommen habe | ||
| ABIVAX | 98,65 | -0,45 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,441 | -1,97 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| IOVANCE BIOTHERAPEUTICS | 2,860 | 0,00 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 | ||
| DENALI THERAPEUTICS | 16,035 | +0,60 % | What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in | ||
| ARGENX | 670,20 | +0,60 % | argenx SE: argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 | ||
| INSMED | 116,34 | +0,10 % | INSMED INC - Stabilität als Basis für den nächsten Impuls | ||
| CAPRICOR | 28,470 | -0,49 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,140 | -2,40 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| REVOLUTION MEDICINES | 121,00 | -1,51 % | TD Cowen bekräftigt Kaufempfehlung für Revolution Medicines nach Daten von Konkurrent Erasca | ||
| PALVELLA THERAPEUTICS | 109,00 | -0,91 % | Palvella Thrives Ahead of Q1 Figures | ||
| SYNDAX PHARMACEUTICALS | 17,815 | -2,60 % | Syndax Pharmaceuticals: BofA hebt Kursziel auf 29 US-Dollar an | ||
| CORVUS PHARMACEUTICALS | 12,865 | -0,50 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors | SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D.,... ► Artikel lesen |
GREENWICH LIFESCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,00 % bei einem Aktienkurs von 24,685 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.